Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: A systematic review and meta-analysis

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Tan, Vanessa Y ^a   Lewis, Sarah J ^a   Adams, Josephine C ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Carcinoma; Fascin 1; Meta analysis; Metastasis; Mortality

Indexed keywords

FASCIN; FASCIN 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER MORTALITY; CARCINOMA; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DISTANT METASTASIS; ESOPHAGUS CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE METASTASIS; META ANALYSIS; METASTASIS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; STOMACH CARCINOMA; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; YOUNG ADULT;

EID: 84874213712     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-52     Document Type: Article

References (82)

1. Diamandis EP. Cancer biomarkers: can we turn recent failures into success?. J Natl Cancer Inst 2010, 102:1462-1467. 10.1093/jnci/djq306, 2950166, 20705936.
2. Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol 2011, 224:289-300. 10.1002/path.2894, 21618240.
3. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int J Biochem Cell Biol 2005, 37:1787-1804. 10.1016/j.biocel.2005.05.004, 16002322.
4. Machesky LM, Li A. Fascin: invasive filopodia promoting metastasis. Commun Integr Biol 2010, 3:263-270. 10.4161/cib.3.3.11556, 2918773, 20714410.
5. Qualtrough D, Singh K, Banu N, Paraskeva C, Pignatelli M. The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro. Br J Cancer 2009, 101:1124-1129. 10.1038/sj.bjc.6605286, 2768091, 19738613.
6. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: an mmunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006, 6:241. 10.1186/1471-2407-6-241, 1615879, 17029629.
7. Takikita M, Hu N, Shou JZ, Giffen C, Wang QH, Wang C, Hewitt SM, Taylor PR. Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma. Anticancer Resh 2011, 31:945-952.
8. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Cai W, Niu Y, Yang Z, Shen Z, Li E. Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol 2006, 59:958-964. 10.1136/jcp.2005.032730, 1860492, 16524962.
9. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005, 11:2597-2605. 10.1158/1078-0432.CCR-04-1378, 15814639.
10. Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C- binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell 2007, 18:4591-4602. 10.1091/mbc.E07-02-0157, 2043557, 17855511.
11. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Lae M, Louvard D, Ben-Ze'ev A, Robine S. Fascin, a novel target of beta-Catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 2007, 67:6844-6853. 10.1158/0008-5472.CAN-07-0929, 17638895.
12. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao JS, Alaoui-Jamali MA, Bismar TA. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 2009, 15:1376-1383. 10.1158/1078-0432.CCR-08-1789, 19228738.
13. Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY. Migrastatin analogues target fascin to block tumour metastasis. Nature 2010, 464:1062-1066. 10.1038/nature08978, 2857318, 20393565.
14. Lecomte N, Njardarson JT, Nagorny P, Yang G, Downey R, Ouerfelli O, Moore MA, Danishefsky SJ. Emergence of potent inhibitors of metastasis in lung cancer via syntheses based on migrastatin. Proc Natl Acad Sci USA 2011, 108:15074-15078. 10.1073/pnas.1015247108, 3174672, 21808037.
15. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH, Chun KH. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010, 138:1035-1045. 10.1053/j.gastro.2009.09.061, 19818782.
16. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
17. Zhang Y, Tong X. Expression of the actin-binding proteins indicates that cofilin and fascin are related to breast tumour size. J Int Med Res 2010, 38:1042-1048.
18. Pinkus GS, Pinkus JL, Langhoff E, Matsumura F, Yamashiro S, Mosialos G, Said JW. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation?. Am J Pathol 1997, 150:543-562. 1858289, 9033270.
19. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005, 11:186-192.
20. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12:1533-1539. 10.1158/1078-0432.CCR-05-2281, 16533778.
21. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS ONE 2011, 6:e27339. 10.1371/journal.pone.0027339, 3208623, 22076152.
22. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000, 83:870-873. 10.1054/bjoc.2000.1395, 2374674, 10970687.
23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
24. Chan C, Jankova L, Fung CL, Clarke C, Robertson G, Chapuis PH, Bokey L, Lin BP, Dent OF, Clarke S. Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Pathol 2010, 34:656-666.
25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16. 10.1186/1745-6215-8-16, 1920534, 17555582.
26. Duchateau L, Collette L, Sylvester R, Pignon JP. Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get!. Biometrics 2000, 56:886-892. 10.1111/j.0006-341X.2000.00886.x, 10985232.
27. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis., http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
30. Gao X, Wu DH. Fascin expression in human epithelial tumors and its clinical significance. Nan Fang Yi Ke Da Xue Xue 2008, 28:953-955.
31. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lu N. Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance. Zhonghua Zhong Liu Za Zhi 2010, 32:838-844.
32. Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab HS, De Manzoni G, Terzi A, Viale G. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility - a clinicopothologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003, 27:1203-1215. 10.1097/00000478-200309000-00003, 12960804.
33. Pelosi G, Pasini F, Fraggetta F, Pastorino U, Iannucci A, Maisonneuve P, Arrigoni G, De Manzoni G, Bresaola E, Viale G. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003, 42:203-213. 10.1016/S0169-5002(03)00294-0, 14568688.
34. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 2008, 8:185. 10.1186/1471-2407-8-185, 2459187, 18590537.
35. Chikman B, Lavy R, Tolstov G, Habler L, Kapiev A, Halevy A, Sandbank J. Significance of Fascin expression in high grade breast cancer. Ann Surg Oncol 2010, 17:S57-S57.
36. Erdogan G, Pestereli HE, Colak T, Karaveli FS, Akaydin M. Fascin expression in invasive ductal carcinoma of breast. Turk Patoloji Dergisi/Turk J Pathol 2010, 26:130-135.
37. Kanber Y, Xu YH, Hartmann DP, Azumi N. Fascin is overexpressed in poorly differentiated colonic carcinomas: possible prognostic indicator of colonic cancer. Am J Clin Pathol 2004, 122:642-642.
38. Kefeli M, Sengul AT, Yildiz L, Baris S, Basoglu A, Kandemir B. EMMPRIN and fascin expression in non-small cell lung carcinoma. Cent Eur J Med 2010, 5:659-665.
39. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997. 10.1158/0008-5472.CAN-07-2017, 18281472.
40. del Rosario A, Goncharuk VN, Tran TA, Sheehan CE, Ross JS. Fascin immunoreactivity correlates with tumor grade in non-small cell lung cancer (NSCLC). Lab Invest 2001, 81:218A.
41. Goncharuk V, Arun B, Middleton L, Sahin A. Assessment of actin-binding protein fascia expression in stage I and II invasive breast cancer. A significant correlation with aggressive clinical behavior. Lab Invest 2003, 83:30A.
42. Lee JH, Bae BH, Lee JM, Kim JM, Hwang JY, Goo JM, Jang JS, Roh MW, Choi SR,. The prognostic significance of fascin expression in colorectal carcinoma, Integrating Science and Technology in Clinical Gastroenterology Asian Pacific Digestive Week 2011 (APDW) Singapore, 1-4 October 2011. J Gastroenterol Hepatol 2011, 26:225. The prognostic significance of fascin expression in colorectal carcinoma, Integrating Science and Technology in Clinical Gastroenterology.
43. Zheng HC, Zheng YS, Xia P, Xu XY, Xing YN, Takahashi H, Guan YF, Takano Y. The pathobiological behaviors and prognosis associated with Japanese gastric adenocarcinomas of pure WHO histological subtypes. Histol Histopathol 2010, 25:445-452.
44. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Eur J Cancer 1999, 35:S200.
45. Rodriguez-Pinilla SM. Fascin and caveolin expression are associated with the basal-like subtype of invasive breast carcinoma. Virchows Archiv 2005, 447:244-245.
46. Xie JJ. Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells. Am J Pathol 2010, 176:939-951. 10.2353/ajpath.2010.090118, 2808098, 20056838.
47. Xue L, Hu N, Song Y, Zou S, Shou J, Qian L, Ren L, Lin D, Tong T, He Z, Zhan QM, Taylor PR, Lu N. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer 2006, 6:296. 10.1186/1471-2407-6-296, 1766359, 17187659.
48. Tsai WC, Chao YC, Sheu LF, Chang JL, Nieh S, Jin JS. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2007, 23:153-160.
49. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T. Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol 2010, 32:90-101.
50. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003, 88:537-547. 10.1038/sj.bjc.6600731, 2377175, 12592367.
51. Oh SY, Kim YB, Suh KW, Paek OJ, Moon HY. Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res 2012, 172:102-108. 10.1016/j.jss.2010.07.015, 20851411.
52. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 2007, 96:1118-1126. 10.1038/sj.bjc.6603690, 2360113, 17375048.
53. Roh MS, Um SJ, Choi Y, Kim KN, Pil JC, Lee SK, Son C, Yang D. Prognostic significance of fascin expression in stage I non-small cell lung cancer. Korean. Tuberc Respir Dis 2008, 65:105-109.
54. Jung EJ, Lee JH, Min BW, Kim YS, Choi JS. Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adenocarcinoma. Indian J Pathol Microbiol 2011, 54:32-36. 10.4103/0377-4929.77320, 21393873.
55. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004, 67:262-270. 10.1159/000081327, 15557788.
56. Li X, Zheng H, Hara T, Takahashi H, Masuda S, Wang Z, Yang X, Guan Y, Takano Y. Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol 2008, 33:69-79.
57. Tsai WC, Jin JS, Chang WK, Chan DC, Yeh MK, Cherng SC, Lin LF, Sheu LF, Chao YC. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: Correlation with clinicopathological parameters. J Histochem Cytochem 2007, 55:955-962. 10.1369/jhc.7A7235.2007, 17510372.
58. Zhao Q, Shen JH, Shen ZY, Wu ZY, Xu XE, Xie JJ, Wu JY, Huang Q, Lu XF, Li EM, Xu LY. Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma. J Histochem Cytochem 2010, 58:979-988. 10.1369/jhc.2010.955765, 2958140, 20713986.
59. Hsu KF, Lin CK, Yu CP, Tzao C, Lee SC, Lee YY, Tsai WC, Jin JS. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus 2009, 22:402-408. 10.1111/j.1442-2050.2008.00921.x, 19207554.
60. Qin YR, Tang H, Qiao JJ, Li FF, Ai JY. Expression of fascin in human esophageal squamous cell carcinoma and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao 2011, 31:1216-1219.
61. Ozerhan IH, Ersoz N, Onguru O, Ozturk M, Kurt B, Cetiner S. Fascin expression in colorectal carcinomas. Clinics 2010, 65:157-164. 10.1590/S1807-59322010000200007, 2827702, 20186299.
62. Kim BG, Ha KW, Park JS, Yoo JH. Immunohistochemical studies of fascin, MMP-9 overexpression, and proliferating index as prognostic factors in cases of a colon adenocarcinoma. Korean. J Korean Soc Coloproctol 2009, 25:393-400.
63. Pang Q, Zhang X, Zhang J, Li Y, Wu W, Wang H, Cui A, Zhang Y. Correlative studies on expression of CXCR4, CXCR12, Fascin and E-cadherin in colorectal carcinoma with lymphatic metastasis. Chinese. Chinese J Clin Oncol 2009, 36:926-929. 933.
64. Choi PJ, Yang DK, Son CH, Lee KE, Lee JI, Roh MS. Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Eur J Cardiothorac Surg 2006, 30:538-542. 10.1016/j.ejcts.2006.06.029, 16870459.
65. Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu T, Gu Z, Wang Y. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett 2010, 290:238-247. 10.1016/j.canlet.2009.09.013, 19819618.
66. Xue LY, Song YM, Tong T, Luo W, Dong LJ, Zou SM, Zheng S, Bi R, Zhan QM, Lu N. Expression of fascin and cytokeratin 14 in esophageal squamous cell carcinoma. Chinese. Zhonghua Yi Xue Za Zhi 2007, 87:2494-2498.
67. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531-533. 10.1038/483531a, 22460880.
68. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009, 100:1219-1229. 10.1038/sj.bjc.6604999, 2676559, 19367280.
69. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001, 323:101-105. 10.1136/bmj.323.7304.101, 1120714, 11451790.
70. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994, 21:403-410.
71. Lundell LR. Etiology and risk factors for esophageal carcinoma. Dig Dis 2010, 28:641-644. 10.1159/000320452, 21088416.
72. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 2011, 11:35. 10.1186/1471-2407-11-35, 3039628, 21269507.
73. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835. 10.1093/jnci/86.11.829, 8182763.
74. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 2011, 104:1440-1451. 10.1038/bjc.2011.110, 3101928, 21448172.
75. Kayani B, Zacharakis E, Ahmed K, Hanna GB. Lymph node metastases and prognosis in oesophageal carcinoma--a systematic review. Eur J Surg Oncol 2011, 37:747-753. 10.1016/j.ejso.2011.06.018, 21839394.
76. Absi A, Adelstein DJ, Rice T. Esophageal Cancer., http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/esophageal-cancer/.
77. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. 3440846, 22522925.
78. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008, 3:46-52. 10.1097/JTO.0b013e31815e8577, 18166840.
79. Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, Nishimura M, Nagai K. Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal?. Jpn J Clin Oncol 2012, 42:189-195. 10.1093/jjco/hyr188, 22210923.
80. Friedenberg F, Fernandez A, Sorondo B, Fazili J, Braitman L. The proximal shift in the distribution of colon cancer is independent of age and gender. J Appl Res Clin Exp Ther 2001, 1.
81. Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004, 13:93-101. 10.1016/j.suronc.2004.08.012, 15572091.
82. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001, 323:224-228. 10.1136/bmj.323.7306.224, 1120839, 11473921.